252 related articles for article (PubMed ID: 15288975)
1. Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey BE; Kapik BM; Kane FE;
Ophthalmology; 2004 Aug; 111(8):1480-8. PubMed ID: 15288975
[TBL] [Abstract][Full Text] [Related]
2. A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data.
Nordmann JP; Mertz B; Yannoulis NC; Schwenninger C; Kapik B; Shams N;
Am J Ophthalmol; 2002 Jan; 133(1):1-10. PubMed ID: 11755834
[TBL] [Abstract][Full Text] [Related]
3. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension.
Alm A; Grunden JW; Kwok KK
J Glaucoma; 2011; 20(4):215-22. PubMed ID: 20520568
[TBL] [Abstract][Full Text] [Related]
4. The effects of unoprostone isopropyl 0.12% and timolol maleate 0.5% on diurnal intraocular pressure.
Stewart WC; Stewart JA; Kapik BM
J Glaucoma; 1998 Dec; 7(6):388-94. PubMed ID: 9871860
[TBL] [Abstract][Full Text] [Related]
5. Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials.
Li N; Chen XM; Zhou Y; Wei ML; Yao X
Clin Exp Ophthalmol; 2006 Nov; 34(8):755-64. PubMed ID: 17073898
[TBL] [Abstract][Full Text] [Related]
6. Unoprostone as adjunctive therapy to timolol: a double masked randomised study versus brimonidine and dorzolamide.
Hommer A; Kapik B; Shams N;
Br J Ophthalmol; 2003 May; 87(5):592-8. PubMed ID: 12714402
[TBL] [Abstract][Full Text] [Related]
7. [Long-term efficacy and safety of combined topical antiglaucoma therapy--timolol & unoprostone vs. betaxolol & unoprostone].
Ohtake Y; Tanino T; Kimura I; Mashima Y; Oguchi Y
Nippon Ganka Gakkai Zasshi; 2004 Jan; 108(1):23-8. PubMed ID: 14969090
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the intraocular pressure-lowering effect of 0.5% timolol maleate and the docosanoid derivative of a PGF2 alpha metabolite, 0.12% unoprostone, in subjects with chronic open-angle glaucoma or ocular hypertension.
Nordmann JP; Rouland JF; Mertz BP
Curr Med Res Opin; 1999; 15(2):87-93. PubMed ID: 10494491
[TBL] [Abstract][Full Text] [Related]
9. A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.
Chiba T; Kashiwagi K; Ishijima K; Furuichi M; Kogure S; Abe K; Chiba N; Tsukahara S
Jpn J Ophthalmol; 2004; 48(2):141-7. PubMed ID: 15060793
[TBL] [Abstract][Full Text] [Related]
10. Adverse periocular reactions to five types of prostaglandin analogs.
Inoue K; Shiokawa M; Higa R; Sugahara M; Soga T; Wakakura M; Tomita G
Eye (Lond); 2012 Nov; 26(11):1465-72. PubMed ID: 23037910
[TBL] [Abstract][Full Text] [Related]
11. Brimonidine 0.2% vs unoprostone 0.15% both added to timolol maleate 0.5% given twice daily to patients with primary open-angle glaucoma or ocular hypertension.
Sharpe ED; Henry CJ; Mundorf TK; Day DG; Stewart JA; Jenkins JN; Stewart WC
Eye (Lond); 2005 Jan; 19(1):35-40. PubMed ID: 15094733
[TBL] [Abstract][Full Text] [Related]
12. Iris-color change developed after topical isopropyl unoprostone treatment.
Yamamoto T; Kitazawa Y
J Glaucoma; 1997 Dec; 6(6):430-2. PubMed ID: 9407373
[TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of UF-021 (Rescula; isopropyl unoprostone).
Yamamoto T; Kitazawa Y; Azuma I; Masuda K
Surv Ophthalmol; 1997 Feb; 41 Suppl 2():S99-103. PubMed ID: 9154284
[TBL] [Abstract][Full Text] [Related]
14. Increased iridial pigmentation in Chinese eyes after use of travoprost 0.004%.
Huang P; Zhong Z; Wu L; Liu W
J Glaucoma; 2009 Feb; 18(2):153-6. PubMed ID: 19225354
[TBL] [Abstract][Full Text] [Related]
15. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
Sherwood MB; Craven ER; Chou C; DuBiner HB; Batoosingh AL; Schiffman RM; Whitcup SM
Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
[TBL] [Abstract][Full Text] [Related]
16. Increase in outflow facility with unoprostone treatment in ocular hypertensive patients.
Toris CB; Zhan G; Camras CB
Arch Ophthalmol; 2004 Dec; 122(12):1782-7. PubMed ID: 15596580
[TBL] [Abstract][Full Text] [Related]
17. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
18. A preliminary risk-benefit assessment of latanoprost and unoprostone in open-angle glaucoma and ocular hypertension.
Eisenberg DL; Camras CB
Drug Saf; 1999 Jun; 20(6):505-14. PubMed ID: 10392667
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution.
Barnebey HS; Orengo-Nania S; Flowers BE; Samples J; Mallick S; Landry TA; Bergamini MV
Am J Ophthalmol; 2005 Jul; 140(1):1-7. PubMed ID: 15990081
[TBL] [Abstract][Full Text] [Related]
20. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.
Mastropasqua L; Carpineto P; Ciancaglini M; Gallenga PE
Ophthalmology; 1999 Mar; 106(3):550-5. PubMed ID: 10080213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
